Additional file 1 of A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs

Additional file 1: Figure S1. The cohort of Shiba Inu dogs tested in this study (a). Twelve skin swab samples and a faecal sample were collected from each dog in each group, resulted in a total of 12 ´ (10+ 10+ 10 + 20) = 600 skin swab samples and 1 ´ (10+ 10 + 10 + 20) = 50 faecal samples. The twelve skin sites include a buccal sample was collected from three groups; cADpre, cADtreat and Healthy, 1 ´ (10+ 10 + 20) = 40 samples. The twelve skin sites are shown in (b); 1. perilabial area (lips), 2. medial pinnae (concave pinnae), 3. axilla, 4. front paw (dorsal and palmar sides combined), 5. hind paw (dorsal and palmar sides combined), 6. cubital flexor (elbow fold), 7. palmar metacarpal (from carpal to metacarpal pad), 8. flank, 9. inguinal area (groin), 10. abdomen, 11. perineum (from genitalia to anus) and 12. ventral tail (proximal). Age distribution of the participating dogs (c), CADESI-04 (d) and PVAS (e) values for each dog were plotted in the graphs. The values of healthy dogs were given as 0. Asterisks (*) indicate the statistically significant difference; **p < 0.01, ***p < 0.001, ***p < 0.0001 (Kruskal-Wallis test). Ten dogs with untreated cAD dogs (cADpre) received oclacitinib treatment for 2 weeks (cADpost). The treatment efficacy was shown as a statistically significant reduction in CADESI-04 (**p < 0.01, Wilcoxon test; f) and PVAS values (p = 0.0078, Wilcoxon test; g). For these 10 dogs, the CADESI-04 score in 12 different skin sites, the perilabial area, medial pinna, axilla, front paw, hind paw, cubital flexor, palmar metacarpal, flank, inguinal area, abdomen, perineum, and ventral tail, is shown in (h). A significant reduction of CADESI-04 score was observed in inguinal area (*p < 0.05; two-way ANOVA).